Early Morning Hearld

Acute Gout Flare Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Acute Gout Flare Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 17
13:54 2020
Acute Gout Flare Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Acute gout Flare Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute gout Flare , historical and forecasted epidemiology as well as the Acute gout Flare market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gout is a systemic disease, which results from the deposition of monosodium urate crystals (MSU) in tissues.

 

Acute gout Flare market report provides current treatment practices, emerging drugs, Acute gout Flare market share of the individual therapies, current and forecasted Acute gout Flare market Size from 2017 to 2030 segmented by seven major markets.

 

Acute gout flares are characterized by distinct inflammatory symptoms (e.g., pain, erythema, swelling), and may cause physical disability, as well as decreased quality of life. Therefore, rapid reduction of auto-inflammation to achieve prompt symptom control is the main goal in managing acute gout. Colchicine, NSAIDs, and glucocorticosteroids are recommended first-line treatment agents for acute gouty flares. The 2016 updated EULAR guidelines recommend considering treatment with an IL-1 inhibitor in patients having frequent flares and in those who are difficult to treat using conventional therapies. Canakinumab is currently the only IL-1 inhibitor that has been registered in Europe for the treatment of gout. 

Current guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) advise that long-term urate-lowering therapy (ULT), with the aim of maintaining serum urate levels (generally below 6 mg/dL), is key to effective control of gout and should be initiated in the presence of certain clinical features: for example, tophi, frequent gouty attacks (flares; two or more per year), and urate arthropathy.

 

Effective options for the treatment of the acute attack include non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids and systemic corticosteroid therapy. With respect to efficacy (although not toxicity) the rapidity with which therapy is commenced appears to be more important than which medication is used. The best choice is often determined by whether or not there are contraindications to NSAID use, such as renal or cardiac insufficiency or a history of peptic ulceration.

 

Provided synovial fluid has been sent for analysis, including culture, it is reasonable to administer intra-articular corticosteroid immediately following joint aspiration (without removing the needle from the joint) when gout appears likely, even though sepsis has not yet been excluded. Systemic corticosteroid therapy can be provided as oral prednisone 20–40 mg daily in divided doses reducing to zero in 10–14 days or intramuscular depot tetracosactrin 1 mg, a synthetic analog of ACTH.

 

 

Colchicine used as the primary treatment of the acute attack is associated with a very high rate of gastrointestinal toxicity. 

 

Scope of the Report

• The report covers the descriptive overview of Acute gout Flare , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Acute gout Flare epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Acute gout Flare are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Acute gout Flare market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute gout Flare market

 

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary of Acute gout Flare

3. Competitive Intelligence Analysis for Acute gout Flare

4. Acute gout Flare : Market Overview at a Glance

4.1. Acute gout Flare Total Market Share (%) Distribution in 2017

4.2. Acute gout Flare Total Market Share (%) Distribution in 2030

5. Acute gout Flare : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Acute gout Flare Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Acute gout Flare Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Acute gout Flare Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Acute gout Flare Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Acute gout Flare Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Acute gout Flare Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Acute gout Flare Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Acute gout Flare Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Acute gout Flare Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute gout Flare Treatment and Management

8.2. Acute gout Flare Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Acute gout Flare Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Acute gout Flare : Seven Major Market Analysis

13.1. Key Findings

13.2. Acute gout Flare Market Size in 7MM

13.3. Acute gout Flare Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Acute gout Flare Total Market Size in the United States

15.1.2. Acute gout Flare Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Acute gout Flare Total Market Size in Germany

15.3.2. Acute gout Flare Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Acute gout Flare Total Market Size in France

15.4.2. Acute gout Flare Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Acute gout Flare Total Market Size in Italy

15.5.2. Acute gout Flare Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Acute gout Flare Total Market Size in Spain

15.6.2. Acute gout Flare Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Acute gout Flare Total Market Size in the United Kingdom

15.7.2. Acute gout Flare Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Acute gout Flare Total Market Size in Japan

15.8.3. Acute gout Flare Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute gout Flare

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/